{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:33:24Z","timestamp":1794555204101,"version":"4.9.1"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that down-regulation of E-cadherin would affect expression of cell matrix adhesion receptors. We show here that inhibition of E-cadherin in ovarian cancer cells causes up-regulation of \u03b15-integrin protein expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently. This greater efficiency could, in turn, be inhibited both in vitro and in vivo with an \u03b15\u03b21-integrin\u2013blocking antibody. When E-cadherin is silenced, \u03b15-integrin is up-regulated through activation of an epidermal growth factor receptor\/FAK\/Erk1\u2013mitogen-activated protein kinase\u2013dependent signaling pathway and not through the canonical E-cadherin\/\u03b2-catenin signaling pathway. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of \u03b15-integrin, i.p. treatment with an \u03b15\u03b21-integrin antibody significantly reduced tumor burden, ascites, and number of metastasis and increased survival by an average of 12 days when compared with IgG treatment (P &amp;lt; 0.0005). \u03b15-Integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. Ten of 107 tissues (9%) had \u03b15-integrin overexpression, and 39% had some level of \u03b15-integrin expression. The median survival for patients with high \u03b15-integrin levels was 26 months versus 35 months for those with low integrin expression (P &amp;lt; 0.05). Taken together, we have identified \u03b15-integrin up-regulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients. [Cancer Res 2008;68(7):2329\u201339]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5167","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T15:44:16Z","timestamp":1207064656000},"page":"2329-2339","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":328,"title":["Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via \u03b15-Integrin, which Is a Therapeutic Target"],"prefix":"10.1158","volume":"68","author":[{"given":"Kenjiro","family":"Sawada","sequence":"first","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban K.","family":"Mitra","sequence":"additional","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Reza","family":"Radjabi","sequence":"additional","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Bhaskar","sequence":"additional","affiliation":[{"name":"6PDL BioPharma, Fremont, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily O.","family":"Kistner","sequence":"additional","affiliation":[{"name":"2Health Studies,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tretiakova","sequence":"additional","affiliation":[{"name":"3Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Jagadeeswaran","sequence":"additional","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Montag","sequence":"additional","affiliation":[{"name":"3Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Becker","sequence":"additional","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary A.","family":"Kenny","sequence":"additional","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus E.","family":"Peter","sequence":"additional","affiliation":[{"name":"4Ben May Department for Cancer Research, and"},{"name":"5Committee on Cancer Biology, University of Chicago, Chicago, Illinois and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"6PDL BioPharma, Fremont, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Diane","family":"Yamada","sequence":"additional","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Lengyel","sequence":"additional","affiliation":[{"name":"1Departments of Obstetrics and Gynecology\/Section of Gynecologic Oncology,"},{"name":"5Committee on Cancer Biology, University of Chicago, Chicago, Illinois and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"2022061623204789000_B1","doi-asserted-by":"crossref","unstructured":"Auersperg N, Wong AST, Choi K, et al. Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev\u20082001; 22: 255\u201388.","DOI":"10.1210\/er.22.2.255"},{"key":"2022061623204789000_B2","doi-asserted-by":"crossref","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med\u20082004; 351: 2519\u201329.","DOI":"10.1056\/NEJMra041842"},{"key":"2022061623204789000_B3","doi-asserted-by":"crossref","unstructured":"Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol\u20082006; 17: 548\u201358.","DOI":"10.1016\/j.ceb.2005.08.001"},{"key":"2022061623204789000_B4","doi-asserted-by":"crossref","unstructured":"Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and IG-cams in cancer. Nat Rev\u20082004; 4: 118\u201332.","DOI":"10.1038\/nrc1276"},{"key":"2022061623204789000_B5","doi-asserted-by":"crossref","unstructured":"Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer\u20081994; 58: 393\u20139.","DOI":"10.1002\/ijc.2910580315"},{"key":"2022061623204789000_B6","doi-asserted-by":"crossref","unstructured":"Darai E, Scoazec JY, Walker-Combrouze F, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol\u20081997; 28: 922\u20138.","DOI":"10.1016\/S0046-8177(97)90007-1"},{"key":"2022061623204789000_B7","doi-asserted-by":"crossref","unstructured":"Symowicz J, Adley BP, Gleason KJ, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res\u20082007; 67: 2030\u20139.","DOI":"10.1158\/0008-5472.CAN-06-2808"},{"key":"2022061623204789000_B8","unstructured":"Cannistra SA, Kansas GS, Niloff J, et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res\u20081993; 53: 3830\u20138."},{"key":"2022061623204789000_B9","doi-asserted-by":"crossref","unstructured":"Ahmed N, Riley C, Oliva K, et al. Ascites induces modulation of a6b1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer\u20082005; 92: 1475\u201385.","DOI":"10.1038\/sj.bjc.6602495"},{"key":"2022061623204789000_B10","unstructured":"Sawada M, Shii J, Akedo H, et al. An experimental model for ovarian tumor invasion of cultured mesothelial cell monolayer. Lab Invest\u20081994; 70: 333\u20138."},{"key":"2022061623204789000_B11","doi-asserted-by":"crossref","unstructured":"Le Floc'h A, Jalil A, Vergnon I, et al. \u03b1E \u03b27 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med\u20082007; 204: 559\u201370.","DOI":"10.1084\/jem.20061524"},{"key":"2022061623204789000_B12","doi-asserted-by":"crossref","unstructured":"Sawada K, Radjabi AR, Shinomiya N, et al. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res\u20082007; 67: 1670\u201380.","DOI":"10.1158\/0008-5472.CAN-06-1147"},{"key":"2022061623204789000_B13","doi-asserted-by":"crossref","unstructured":"Shell S, Park S, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A\u20082007; 104: 11400\u20135.","DOI":"10.1073\/pnas.0704372104"},{"key":"2022061623204789000_B14","doi-asserted-by":"crossref","unstructured":"Boles BK, Ritzenthaler J, Birkenmeier T, et al. Phorbol ester-induced U-937 differentiation: effects on integrin a5 gene transcription. Am J Physiol Cell Mol Physiol\u20082000; 278: 703\u201312.","DOI":"10.1152\/ajplung.2000.278.4.L703"},{"key":"2022061623204789000_B15","doi-asserted-by":"crossref","unstructured":"Kenny HA, Krausz T, Yamada SD, et al. Development of an organotypic peritoneal three-dimensional culture to study peritoneal attachment of ovarian cancer cells. Int J Cancer\u20082007; 121: 1463\u201372.","DOI":"10.1002\/ijc.22874"},{"key":"2022061623204789000_B16","doi-asserted-by":"crossref","unstructured":"Lengyel E, Schmalfeldt B, Konik E, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol\u20082001; 82: 291\u20138.","DOI":"10.1006\/gyno.2001.6243"},{"key":"2022061623204789000_B17","doi-asserted-by":"crossref","unstructured":"Lengyel E, Wang H, Gum R, et al. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular-signal regulated kinase 1 dependent signaling cascade. Oncogene\u20081997; 14: 2563\u201374.","DOI":"10.1038\/sj.onc.1201098"},{"key":"2022061623204789000_B18","doi-asserted-by":"crossref","unstructured":"Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2\/Neu. Int J Cancer\u20082005; 113: 678\u201382.","DOI":"10.1002\/ijc.20598"},{"key":"2022061623204789000_B19","doi-asserted-by":"crossref","unstructured":"Mell LK, Meyer JJ, Tretiakova MS, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res\u20082004; 10: 5546\u201353.","DOI":"10.1158\/1078-0432.CCR-0943-03"},{"key":"2022061623204789000_B20","doi-asserted-by":"crossref","unstructured":"Wingerter P, Kazman I, Norberg S, et al. Uniform overexpression and rapid accessibility of a5b1 integrin on blood vessels in tumors. Am J Pathol\u20082005; 167: 193\u2013211.","DOI":"10.1016\/S0002-9440(10)62965-3"},{"key":"2022061623204789000_B21","doi-asserted-by":"crossref","unstructured":"Hynes R. Integrins: versatility, modulation, and signaling in cell adhesion. Cell\u20081992; 69: 11\u201325.","DOI":"10.1016\/0092-8674(92)90115-S"},{"key":"2022061623204789000_B22","doi-asserted-by":"crossref","unstructured":"Nhieu G, Isberg R. Bacterial internalization mediated by b1chain integrins is determined by ligand affinity and receptor density. EMBO J\u20081993; 12: 1887\u201395.","DOI":"10.1002\/j.1460-2075.1993.tb05837.x"},{"key":"2022061623204789000_B23","doi-asserted-by":"crossref","unstructured":"Hoschuetzky H, Aberle H, Kemler R. \u03b2-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol\u20081994; 127: 1375\u201380.","DOI":"10.1083\/jcb.127.5.1375"},{"key":"2022061623204789000_B24","unstructured":"Adachi A, Taki T, Higashiyama M, et al. Significance of integrin-\u03b15 gene expression as a prognostic factor in node-negative non small cell lung cancer. Clin Cancer Res\u20082000; 6: 96\u2013101."},{"key":"2022061623204789000_B25","doi-asserted-by":"crossref","unstructured":"Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 2006;23:65\u201374.","DOI":"10.1007\/s10585-006-9020-3"},{"key":"2022061623204789000_B26","doi-asserted-by":"crossref","unstructured":"Makarla PB, Saboorian MH, Ashfaq R, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res\u20082005; 11: 5365\u20139.","DOI":"10.1158\/1078-0432.CCR-04-2455"},{"key":"2022061623204789000_B27","unstructured":"Shibata K, Kikkawa F, Nawa A, et al. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res\u20081997; 57: 5416\u201320."},{"key":"2022061623204789000_B28","doi-asserted-by":"crossref","unstructured":"Strobel T, Cannistra SA. b1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol\u20081999; 73: 362\u20137.","DOI":"10.1006\/gyno.1999.5388"},{"key":"2022061623204789000_B29","doi-asserted-by":"crossref","unstructured":"Casey RC, Burleson KM, Skubitz KM, et al. b1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol\u20082001; 159: 2071\u201380.","DOI":"10.1016\/S0002-9440(10)63058-1"},{"key":"2022061623204789000_B30","doi-asserted-by":"crossref","unstructured":"Maschler S, Wirl G, Spring H, et al. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene\u20082005; 24: 2032\u201341.","DOI":"10.1038\/sj.onc.1208423"},{"key":"2022061623204789000_B31","doi-asserted-by":"crossref","unstructured":"Munshi HG, Ghosh S, Mukhopadhyay S, et al. Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes. J Biol Chem\u20082002; 277: 38159\u201367.","DOI":"10.1074\/jbc.M202384200"},{"key":"2022061623204789000_B32","doi-asserted-by":"crossref","unstructured":"Niedbala MJ, Crickard K, Bernacki R. Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. Exp Cell Res\u20081985; 160: 499\u2013513.","DOI":"10.1016\/0014-4827(85)90197-1"},{"key":"2022061623204789000_B33","doi-asserted-by":"crossref","unstructured":"Heath R, Jayne D, O'Leary R, et al. Tumor-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand\/Fas interaction. Br J Cancer\u20082004; 90: 1437\u201342.","DOI":"10.1038\/sj.bjc.6601635"},{"key":"2022061623204789000_B34","doi-asserted-by":"crossref","unstructured":"Wong AST, Gumbiner BM. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol\u20082003; 161: 1191\u2013203.","DOI":"10.1083\/jcb.200212033"},{"key":"2022061623204789000_B35","doi-asserted-by":"crossref","unstructured":"Qian X, Karpova T, Sheppard AM, et al. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J\u20082004; 23: 1739\u201348.","DOI":"10.1038\/sj.emboj.7600136"},{"key":"2022061623204789000_B36","doi-asserted-by":"crossref","unstructured":"Kim S, Bell K, Mousa SA, et al. Regulation of angiogenesis in vivo by ligation of integrin a5b1 with the central cell-binding domain of fibronectin. Am J Pathol\u20082000; 156: 1345\u201362.","DOI":"10.1016\/S0002-9440(10)65005-5"},{"key":"2022061623204789000_B37","doi-asserted-by":"crossref","unstructured":"Magnussen A, Kasman I, Norberg S, et al. Rapid access of antibodies to a5b1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res\u20082005; 65: 2712\u201321.","DOI":"10.1158\/0008-5472.CAN-04-2691"},{"key":"2022061623204789000_B38","unstructured":"Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an anti-a5b1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol\u20082007; 5: 273\u201386."},{"key":"2022061623204789000_B39","doi-asserted-by":"crossref","unstructured":"Maglott A, Bartik P, Cosgun S, et al. The small a5b1 integrin antagonist, SJ749, reduces proliferation and clonogencity of human astrocytoma cells. Cancer Res\u20082006; 66: 6002\u20138.","DOI":"10.1158\/0008-5472.CAN-05-4105"},{"key":"2022061623204789000_B40","doi-asserted-by":"crossref","unstructured":"Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin a5b1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer\u20082003; 104: 496\u2013503.","DOI":"10.1002\/ijc.10958"},{"key":"2022061623204789000_B41","unstructured":"Livant DL, Brabec RK, Pienta KJ, et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res\u20082000; 60: 309\u201320."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/7\/2329\/2591732\/2329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/7\/2329\/2591732\/2329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:41:25Z","timestamp":1655419285000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/7\/2329\/540618\/Loss-of-E-Cadherin-Promotes-Ovarian-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2008,4,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5167","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22370039","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370039.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496241.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496241","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}